487 related articles for article (PubMed ID: 16545870)
21. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
22. Soluble HLA revisited.
Tabayoyong WB; Zavazava N
Leuk Res; 2007 Feb; 31(2):121-5. PubMed ID: 16860865
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
24. Soluble total human leukocyte antigen class I and human leukocyte antigen-G molecules in kidney and kidney/pancreas transplantation.
Rebmann V; Bartsch D; Wunsch A; Möllenbeck P; Golda T; Viebahn R; Grosse-Wilde H
Hum Immunol; 2009 Dec; 70(12):995-9. PubMed ID: 19651178
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma.
Wu L; Wang T; Gui W; Lin H; Xie K; Wang H; Gao T; Zhang X; Liu L; Han T; Tian Y; Hou L
Oncology; 2014; 87(1):40-7. PubMed ID: 24969158
[TBL] [Abstract][Full Text] [Related]
26. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
Li D; Li G; Wang B
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
[TBL] [Abstract][Full Text] [Related]
27. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
29. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
30. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
Pedersen LM; Klausen TW; Davidsen UH; Johnsen HE
Ann Hematol; 2005 Aug; 84(8):510-6. PubMed ID: 15834569
[TBL] [Abstract][Full Text] [Related]
31. The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment.
Enrici RM; Anselmo AP; Iacari V; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
Haematologica; 1998 Jul; 83(7):636-44. PubMed ID: 9718869
[TBL] [Abstract][Full Text] [Related]
32. [Does beta-2 microglobulin measurement play role in diagnostics of childhood malignancies?].
Bień E; Balcerska A; Ciesielski D
Wiad Lek; 2004; 57(1-2):8-11. PubMed ID: 15181741
[TBL] [Abstract][Full Text] [Related]
33. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
34. Quantification and identification of soluble HLA-G isoforms.
Rebmann V; LeMaoult J; Rouas-Freiss N; Carosella ED; Grosse-Wilde H
Tissue Antigens; 2007 Apr; 69 Suppl 1():143-9. PubMed ID: 17445190
[TBL] [Abstract][Full Text] [Related]
35. [Tumor markers in malignant lymphoma].
Kato H; Ogura M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
[TBL] [Abstract][Full Text] [Related]
36. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
Bono P; Teerenhovi L; Joensuu H
Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
[TBL] [Abstract][Full Text] [Related]
40. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
